Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 4/20 | 0.46 |
| ▸ | POLB | P06746 | 1/20 | 0.45 |
| ▸ | RECQL | P46063 | 1/20 | 0.45 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.45 |
| ▸ | MEN1 | O00255 | 3/20 | 0.43 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.43 |
| ▸ | CTSD | P07339 | 5/20 | 0.43 |
| ▸ | NPC1 | O15118 | 1/20 | 0.40 |
| ▸ | RAB9A | P51151 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | MCHR1 | Q99705 | 1/20 | 0.38 |
| ▸ | GAA | P10253 | 1/20 | 0.38 |
| ▸ | HPGD | P15428 | 1/20 | 0.38 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7543076 | 1.00 | KMT2A (0.46) | KMT2APOLBRECQLTDP1MEN1 | |
| SCHEMBL7543080 | 1.00 | KMT2A (0.46) | KMT2APOLBRECQLTDP1MEN1 | |
| SCHEMBL7541940 | 1.00 | KMT2A (0.46) | KMT2APOLBRECQLTDP1MEN1 | |
| SCHEMBL7544507 | 0.94 | KMT2A (0.46) | KMT2APOLBRECQLTDP1MEN1 | |
| SCHEMBL7543666 | 0.94 | KMT2A (0.46) | KMT2APOLBRECQLTDP1MEN1 | |
| SCHEMBL7550028 | 0.94 | KMT2A (0.46) | KMT2APOLBRECQLTDP1MEN1 | |
| SCHEMBL7543669 | 0.94 | KMT2A (0.46) | KMT2APOLBRECQLTDP1MEN1 | |
| SCHEMBL7543665 | 0.94 | KMT2A (0.46) | KMT2APOLBRECQLTDP1MEN1 | |
| SCHEMBL7544564 | 0.89 | KMT2A (0.44) | KMT2AMEN1CTSDALDH1A1HPGD | |
| SCHEMBL7544558 | 0.89 | KMT2A (0.44) | KMT2AMEN1CTSDALDH1A1HPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2002053546-A1 | HETEROCYCLE DERIVATIVES AS PPAR-GAMMA AGONISTS | ADVANCED SYNTECH, LLC (US) | 2002-07-11 | — | — | WO | claimed |
| US-20020082263-A1 | Heterocycle derivatives as PPAR-gamma agonists | ADVANCED SYNTECH LLC | 2002-06-27 | — | — | US | claimed |
| US-20020082263-A1 | Heterocycle derivatives as PPAR-gamma agonists | ADVANCED SYNTECH LLC | 2002-06-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020082263-A1 | Heterocycle derivatives as PPAR-gamma agonists | PPARG, PPARD, PPARA | KMT2A 2543/4885POLB 1886/4885RECQL 3736/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.